Fulltext

Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes

Krebs, Andreas ; Doerfer, Juergen ; Krause, Alexandra ; Grulich-Henn, Juergen ; Holder, Martin ; Hecker, Wolfgang ; Lichte, Kai ; Schmidt-Trucksaess, Arno ; Winkler, Karl ; Schwab, Karl Otfried

In: Journal of Pediatric Endocrinology and Metabolism, 2016, vol. 29, no. 10, p. 1181-1186

Add to personal list
    Title
    • Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes
    Author
    • Krebs, Andreas. Department of Pediatrics and Adolescence Medicine, University Hospital, 79106 Freiburg, Germany
    • Doerfer, Juergen. Department of Pediatrics and Adolescence Medicine, University Hospital, 79106 Freiburg, Germany
    • Krause, Alexandra. Department of Pediatrics and Adolescence Medicine, University Hospital, 79106 Freiburg, Germany
    • Grulich-Henn, Juergen. Department of Pediatrics and Adolescence Medicine, University Hospital, 69120 Heidelberg, Germany
    • Holder, Martin. Children's Hospital, Olgahospital, 70176 Stuttgart, Germany
    • Hecker, Wolfgang. Children's Hospital, Olgahospital, 70176 Stuttgart, Germany
    • Lichte, Kai. Clinic for Pediatrics and Adolescent Medicine, Schwarzwald-Baar Medical Center, 78050 Villingen-Schwenningen, Germany
    • Schmidt-Trucksaess, Arno. Institute of Exercise and Health Sciences, University of Basel, Basel, Switzerland
    • Winkler, Karl. Department of Clinical Chemistry, University Hospital, 79095 Freiburg, Germany
    • Schwab, Karl Otfried. Department of Pediatrics and Adolescence Medicine, University Hospital, 79106 Freiburg, Germany
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Journal of Pediatric Endocrinology and Metabolism, 2016, vol. 29, no. 10, p. 1181-1186. De Gruyter
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:326022
    Summary
    AbstractBackground: The objective of the study was to assess the effect of atorvastatin on inflammation markers and low-density lipoprotein (LDL) subfractions. Methods: In a prospective, randomized, double-blind pilot study involving 28 adolescents with type 1 diabetes (T1D), lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, high-sensitivity C-reactive protein (hsCRP), and subfractions of LDL were measured at baseline, after 1 year and 2 years of treatment with atorvastatin (10 mg/day) vs. placebo. Results: For the atorvastatin group, we found posttreatment reductions of Lp-PLA2 activity (p<0.001), LDL cholesterol (p=0.001), non-small dense LDL cholesterol (p<0.001), total cholesterol (p<0.001), and apolipoprotein B (apo B) (p<0.001), whereas small dense LDL cholesterol and hsCRP did not change significantly. Conclusions: In adolescents with T1D, long-term treatment with atorvastatin is safe and may reduce cardiovascular risk by significant decreases of Lp-PLA2 activity and LDL cholesterol.